Wells Fargo Lowers CVS Price Target to $102, Maintains Overweight Rating

miércoles, 3 de diciembre de 2025, 3:18 pm ET1 min de lectura
CVS--

Wells Fargo analyst Stephen Baxter lowered the price target for CVS Health Corporation to $102 from $103 while maintaining an Overweight rating. Q3 results were solid, but the bullish outlook for the Health Care Benefits segment in 2025 is tempered by a steeper Part D medical loss ratio. CVS is adapting to industry demands and implementing initiatives to improve margins and profitability.

Wells Fargo Lowers CVS Price Target to $102, Maintains Overweight Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios